Anti-infective Agents : Carbapenem
IFINI1 “Finibax injection” 0.25 gm/vial
適應症：對Doripenem Hydrate具感受性之菌種的複雜性泌尿道感染(包括腎盂腎炎)及複雜性腹腔內感染。
Usual dose: duration includes at least 3 days of IV therapy and switch to appropriate oral therapy.
Adult:
Intra-abdominal infection, complicated, severe: 500 mg Q8H IV for 5-14 days
Urinary tract infection (complicated) or pyelonephritis: 500 mg Q8H IV for 10-14 days
Intravenous catheter-related bloodstream infection (off-label use): 500 mg Q8H IV for 7-14 days.
Pediatric: safety and effectiveness not established
Dose adjustment:
Renal Impairment:CrCl >50 mL/minute: No adjustment necessary; CrCl 30-50 mL/minute: 250 mg Q8H; CrCl 11-29 mL/minute: 250 mg q12h.
Intermittent HD: 250 mg qd; if treating infections caused by pseudomonas aeruginosa, administer 500 mg q12h on day 1, followed by 500 mg qd.
CVVHDF: 250 mg Q12H
Hepatic impairment: no dosage adjustments
Contraindication:
Known serious hypersensitivity to doripenem or other carbapenems or any component of the formulation; anaphylactic reactions to beta-lactam antibiotics.
Precaution:
Neurologic: seizures have been reported; use caution with preexisting CNS disorders and adjust dose in renal impairment to avoid drug accumulation. Patients receiving doses >500 mg Q8H may increase risk of seizures.
Gastrointestinal: Use may result in C. difficile-associated diarrhea (CDAD) and pseudomembranous colitis.
Adverse effect:
Common: Phlebitis, rash, diarrhea, nausea, anemia, increased liver enzymes, headache
Serious: Stevens-Johnson syndrome, toxic epidermal necrolysis, clostridium difficile colitis, anaphylaxis, seizure, renal failure.